Genfit SA

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

10 Jun 2024 16:22:00 By Nasdaq GlobeNewswire

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

29 May 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

22 May 2024 11:05:00 By Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2024 Financial Information

14 May 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

25 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

15 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

05 Apr 2024 13:00:00 By Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

04 Apr 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2023

29 Feb 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces 2024 Financial Calendar  

15 Jan 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

11 Jan 2024 15:10:00 By Nasdaq GlobeNewswire

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

08 Dec 2023 00:55:00 By Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 Dec 2023 04:15:01 By Nasdaq GlobeNewswire

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

06 Dec 2023 10:30:00 By Nasdaq GlobeNewswire

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

16 Nov 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2023 Financial Information

09 Nov 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

02 Nov 2023 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology  

26 Sep 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

20 Sep 2023 15:10:00 By Nasdaq GlobeNewswire